This page shows you your search results in order of date.
Order by Relevance | Date
Total 21938 results found since Jan 2013.
Glioma Response to IDH Inhibition: Real-World Experience
Clin Cancer Res. 2023 Sep 22. doi: 10.1158/1078-0432.CCR-23-2164. Online ahead of print.ABSTRACTTreatment of IDH mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. IDH inhibition has a therapeutic benefit in patients with these tumors.PMID:37738033 | DOI:10.1158/1078-0432.CCR-23-2164
Source: Clinical Cancer Research - September 22, 2023 Category: Cancer & Oncology Authors: Rimas V Lukas Craig Horbinski Source Type: research
Prognosis and immunoinfiltration analysis of angiogene-related genes in grade 4 diffuse gliomas
Aging (Albany NY). 2023 Sep 21;15. doi: 10.18632/aging.205054. Online ahead of print.ABSTRACTAlthough angiogenesis critically influences the progression of solid tumors, its contribution to highly malignant, grade 4 diffuse gliomas remains unclear. After analyzing 506 angiogenesis-related genes differentially expressed in grade 4 diffuse gliomas via LASSO and univariate and multivariate COX regression analyses, we constructed a nomogram based on COL22A1, IGFBP2, and MPO that accurately predicted patient survival. The nomogram's performance was validated in an external patient cohort, and a risk score based on the formula C...
Source: Aging - September 22, 2023 Category: Biomedical Science Authors: Hui Liu Zhirui Zeng Peng Sun Source Type: research
Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies
CONCLUSIONS: In this study we report that an inherent enrichment of distinct GSCs pools underpin the functional inter-cluster variances displayed by GBM patients. We uncover two selectively represented novel functional biomarkers capable of discriminating GBM patients' stratification, survival and drug response, setting the stage for the determination of patient-tailored diagnostic and prognostic strategies and, mostly, for the design of appropriate, patient-selective treatment protocols.PMID:37735434 | DOI:10.1186/s13046-023-02811-0
Source: Cell Research - September 22, 2023 Category: Cytology Authors: Alberto Visioli Nadia Trivieri Gandino Mencarelli Fabrizio Giani Massimiliano Copetti Orazio Palumbo Riccardo Pracella Maria Grazia Cariglia Chiara Barile Luigi Mischitelli Amata Amy Soriano Pietro Palumbo Federico Legnani Francesco DiMeco Leonardo Gorgog Source Type: research
Preclinical Brain Tumor Models
Conditions: Brain Metastases; Diffuse Gliomas Intervention: Other: Fresh tumor sampling Sponsor: Assistance Publique Hopitaux De Marseille Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Condition: Glioma Intervention: Biological: DC vaccine Sponsor: Huashan Hospital Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Preclinical Brain Tumor Models
Conditions: Brain Metastases; Diffuse Gliomas Intervention: Other: Fresh tumor sampling Sponsor: Assistance Publique Hopitaux De Marseille Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Condition: Glioma Intervention: Biological: DC vaccine Sponsor: Huashan Hospital Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Preclinical Brain Tumor Models
Conditions: Brain Metastases; Diffuse Gliomas Intervention: Other: Fresh tumor sampling Sponsor: Assistance Publique Hopitaux De Marseille Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Research Progress in Immunotherapy of Gliomas
J Integr Neurosci. 2023 Aug 14;22(5):118. doi: 10.31083/j.jin2205118.ABSTRACTAlthough some progress has been made in tumor treatment, gliomas remain one of the tumors that can still seriously threaten human life and health. Due to the particularity of the immune microenvironment of the central nervous system and the strong invasiveness of tumors, the treatment of gliomas remains a major challenge. Currently, researchers have explored a large number of immunotherapy programs to improve the survival and prognosis of glioma patients, including tumor vaccines, immune checkpoint inhibitors, adoptive cell transfer therapy, viral...
Source: Journal of Integrative Neuroscience - September 21, 2023 Category: Neuroscience Authors: Zhi-Hong Duan Zi-Long Wei Source Type: research
< em > PLEKHA4 < /em > is Associated with Tumour Microenvironment, Stemness, Proliferation and Poor Prognosis of Gliomas
CONCLUSIONS: PLEKHA4 is highly expressed in glioma tissues and correlated with tumour stemness, immune cell infiltration and proliferation, suggesting its potential as a novel prognostic biomarker and therapeutic target in glioma.PMID:37735118 | DOI:10.31083/j.jin2205130
Source: Journal of Integrative Neuroscience - September 21, 2023 Category: Neuroscience Authors: Xin Gao Yukun Liu Shunming Hong Hui Yang Bing Guan Xiaodong Ma Source Type: research
Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies
Glioblastoma (GBM) is the most malignant among gliomas with an inevitable lethal outcome. The elucidation of the physiology and regulation of this tumor is mandatory to unravel novel target and effective thera...
Source: Journal of Experimental and Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Alberto Visioli, Nadia Trivieri, Gandino Mencarelli, Fabrizio Giani, Massimiliano Copetti, Orazio Palumbo, Riccardo Pracella, Maria Grazia Cariglia, Chiara Barile, Luigi Mischitelli, Amata Amy Soriano, Pietro Palumbo, Federico Legnani, Francesco DiMeco, L Tags: Research Source Type: research
Tumor mutation burden-related histopathological features for predicting overall survival in gliomas using graph deep learning
This study aimed to identify the TMB-related histopathological features from hematoxylin and eosin slides and explore their prognostic value in gliomas. We detected the TMB-related features using a graph convolutional neural network from whole slide image (WSI) of patients from The Cancer Genome Atlas dataset (619 patients), and evaluated the correlation between features and TMB in an external validation set (237 patients).
Source: American Journal of Pathology - September 21, 2023 Category: Pathology Authors: Caixia Sun, Tao Luo, Zhenyu Liu, Jia Ge, Lizhi Shao, Xiangyu Liu, Bao Li, Song Zhang, Qi Qiu, Wei Wei, Shuo Wang, Xiu-Wu Bian, Jie Tian Tags: Regular Article Source Type: research
The role of APOBEC3C in modulating the tumor microenvironment and stemness properties of glioma: evidence from pancancer analysis
ConclusionThe A3 family exhibits heterogeneous expression across various cancer types, with its expression profile serving as a predictive marker for overall survival in glioma patients. A3C emerges as a regulator of glioma progression, exerting its influence through modulation of the tumor microenvironment and regulation of stemness.
Source: Frontiers in Immunology - September 21, 2023 Category: Allergy & Immunology Source Type: research
Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
Low grade gliomas (LGGs) of pineal region are usually difficult to remove and they frequently relapse or progress after front line chemotherapy. Bevacizumab-Irinotecan (BEVIRI) combination has been successfully attempted in children with recurrent LGGs, in most cases not previously irradiated. The efficacy of bevacizumab has also been described in radiation necrosis. Considering the possible overlapping of radiation treatment effect and disease progression and difficulty in differentiating, we report on the use of BEVIRI in a case of a recurrent relapsing low-grade glioma of the pineal region, subjected to multiple neurosu...
Source: Frontiers in Oncology - September 20, 2023 Category: Cancer & Oncology Source Type: research
